ANXA2, PRKCE, and OXT are critical differentially genes in nonalcoholic fatty liver disease
Gastroenterology and Hepatology from Bed to Bench,
Vol. 12 No. 2 (2019),
18 March 2019
,
Page 131-137
https://doi.org/10.22037/ghfbb.v12i2.1563
Abstract
Aim: Identification of prominent genes which are involved in onset and progress of steatosis stage of Nonalcoholic fatty liver disease (NAFLD) is the aim of this study.
Background: NAFLD is characterized by accumulation of lipids in hepatocytes. The patients with steatosis (the first stage of NAFLD) will come across nonalcoholic steatohepatitis (NASH) and finally hepatic cirrhosis. There is correlation between cirrhosis and hepatic cancer. However, ultrasonography is used to diagnose NAFLD, biopsy is the precise diagnostic method.
Methods: Gene expression profiles of 14 steatosis patients and 14 controls are retrieved from gene expression omnibus (GEO) and after statistical validation top 250 differentially expressed genes (DEGs) were determined. The characterized DEGs were included in network analysis and the central DEGs were identified. Gene ontology (GO) performed by ClueGO analysis of DEGs to determine critical biological terms. Role of prominent DEGs in steatosis is discussed in details.
Results: Numbers of 31 significant DEGs including 20 up-regulated and 11 down-regulated ones were determined. Nine biological groups including 27 terms were recognized. Negative regulation of low-density lipoprotein particle receptor catabolic process, TRAM-dependent toll-like receptor signaling pathway, and regulation of hindgut contraction which were related to ANXA2, PRKCE, and OXT respectively were determined as critical biological term groups and DEGS.
Conclusion: Deregulation of ANXA2, PRKCE, and OXT is a critical event in steatosis. It seems these three genes are suitable biomarker to diagnosis of steatosis.
Keywords: Nonalcoholic fatty liver disease, Biomarker, Gene.
(Please cite as: Rezaei Tavirani M, Rezaei Tavirani M, Zamanian Azodi M. ANXA2, PRKCE, and OXT are critical differentially genes in Nonalcoholic fatty liver disease. Gastroenterol Hepatol Bed Bench 2019;12(2):131-137).
- Nonalcoholic fatty liver disease
- Biomarker
- Gene.
How to Cite
References
Ekstedt M, Franzén LE, Mathiesen UL, Thorelius L, Holmqvist M, Bodemar G, et al. Long‐term follow‐up of patients with NAFLD and elevated liver enzymes. Hepatol 2006;44:865-73.
Gaggini M, Morelli M, Buzzigoli E, DeFronzo R, Bugianesi E, Gastaldelli A. Non-alcoholic fatty liver disease (NAFLD) and its connection with insulin resistance, dyslipidemia, atherosclerosis and coronary heart disease. Nut 2013;5:1544-60.
Muto Y, Sato S, Watanabe A, Moriwaki H, Suzuki K, Kato A, et al. Overweight and obesity increase the risk for liver cancer in patients with liver cirrhosis and long-term oral supplementation with branched-chain amino acid granules inhibits liver carcinogenesis in heavier patients with liver cirrhosis. Hepatol Res 2006;35:204-14.
Altinbas A, Sowa JP, Hasenberg T, Canbay A. The diagnosis and treatment of non-alcoholic fatty liver disease. Minerva Gastroenterol Dietol. 2015;61:159-69.
Naik A, Košir R, Rozman D. Genomic aspects of NAFLD pathogenesis. Genomics 2013;102:84-95.
Younossi ZM, Baranova A, Ziegler K, Del Giacco L, Schlauch K, Born TL, et al. A genomic and proteomic study of the spectrum of nonalcoholic fatty liver disease. Hepatol 2005;42:665-74.
Kalhan SC, Guo L, Edmison J, Dasarathy S, McCullough AJ, Hanson RW, et al. Plasma metabolomic profile in nonalcoholic fatty liver disease. Metabolism 2011;60:404-13.
Yu C, Xu C, Xu L, Yu J, Miao M, Li Y. Serum proteomic analysis revealed diagnostic value of hemoglobin for nonalcoholic fatty liver disease. J Hepatol 2012;56:241-7.
Pearce SG, Thosani NC, Pan JJ. Noninvasive biomarkers for the diagnosis of steatohepatitis and advanced fibrosis in NAFLD. Biomark Res 2013;1:7.
Feldstein AE, Wieckowska A, Lopez AR, Liu YC, Zein NN, McCullough AJ. Cytokeratin‐18 fragment levels as noninvasive biomarkers for nonalcoholic steatohepatitis: a multicenter validation study. Hepatol 2009;50:1072-8.
Safaei A, Tavirani MR, Oskouei AA, Azodi MZ, Mohebbi SR, Nikzamir AR. Protein-protein interaction network analysis of cirrhosis liver disease. Gastroenterol Hepatol Bed Bench 2016;9:114.
Safari-Alighiarloo N, Taghizadeh M, Rezaei-Tavirani M, Goliaei B, Peyvandi AA. Protein-protein interaction networks (PPI) and complex diseases. Gastroenterol Hepatol Bed Bench 2014;7:17.
Rezaei-Tavirani M, Mansouri V, Mahdavi SM, Valizadeh R, Rostami-Nejad M, Zali MR. Introducing crucial protein panel of gastric adenocarcinoma disease. Gastroenterol Hepatol Bed Bench 2017;10:21-8.
Ahrens M, Ammerpohl O, Von Schönfels W, Kolarova J, Bens S, Itzel T, et al. DNA methylation analysis in nonalcoholic fatty liver disease suggests distinct disease-specific and remodeling signatures after bariatric surgery. Cell Metab 2013;18:296-302.
Zhi J, Sun J, Wang Z, Ding W. Support vector machine classifier for prediction of the metastasis of colorectal cancer. Int J Mol Med 2018;41:1419-26.
Szklarczyk D, Morris JH, Cook H, Kuhn M, Wyder S, Simonovic M, et al. The STRING database in 2017: quality-controlled protein–protein association networks, made broadly accessible. Nucleic Acids Res 2017;45:D362-8.
Tian R, Li X, Gao Ye, Li Y, Yang P, Wang K. Identification and validation of the role of matrix metalloproteinase-1 in cervical cancer. Int J Oncol 2018;52:1198-208.
Sgroi DC, Teng S, Robinson G, LeVangie R, Hudson JR, Elkahloun AG. In vivo gene expression profile analysis of human breast cancer progression. Cancer Res 1999;59:5656-61.
Loring J, Wen X, Lee J, Seilhamer J, Somogyi R. A gene expression profile of Alzheimer's disease. DNA Cell Biol 2001;20:683-95.
Goldstein JL, Brown MS. Regulation of low-density lipoprotein receptors: implications for pathogenesis and therapy of hypercholesterolemia and atherosclerosis. Circul 1987;76:504-7.
Sun DQ, Liu WY, Wu SJ, Zhu GQ, Braddock M, Zhang DC, et al. Increased levels of low-density lipoprotein cholesterol within the normal range as a risk factor for nonalcoholic fatty liver disease. Oncotarget 2016;7:5728.
Perreault M, Białek A, Trottier J, Verreault M, Caron P, Milkiewicz P, et al. Role of glucuronidation for hepatic detoxification and urinary elimination of toxic bile acids during biliary obstruction. Plos One 2013;8:e80994.
Naik A, Belič A, Zanger UM, Rozman D. Molecular interactions between NAFLD and xenobiotic metabolism. Front Genet 2013;4:2.
- Abstract Viewed: 110 times
- PDF Downloaded: 71 times